These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 28944709)

  • 1. The cardiometabolic effect of current management of polycystic ovary syndrome: strategies of prevention and treatment.
    Baldani DP; Skrgatic L; Ougouag R; Kasum M
    Gynecol Endocrinol; 2018 Feb; 34(2):87-91. PubMed ID: 28944709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of cardiometabolic complications in polycystic ovary syndrome: Unmet needs.
    Yanes Cardozo LL; Romero DG
    FASEB J; 2021 Nov; 35(11):e21945. PubMed ID: 34606638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obesity, type 2 diabetes mellitus and cardiovascular disease risk: an uptodate in the management of polycystic ovary syndrome.
    Orio F; Muscogiuri G; Nese C; Palomba S; Savastano S; Tafuri D; Colarieti G; La Sala G; Colao A; Yildiz BO
    Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():214-219. PubMed ID: 27575870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic and cardiovascular consequences of polycystic ovary syndrome.
    Orio F; Vuolo L; Palomba S; Lombardi G; Colao A
    Minerva Ginecol; 2008 Feb; 60(1):39-51. PubMed ID: 18277351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of PCOS in adolescence.
    Warren-Ulanch J; Arslanian S
    Best Pract Res Clin Endocrinol Metab; 2006 Jun; 20(2):311-30. PubMed ID: 16772160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of pharmaceutical intervention on lipid profile in polycystic ovary syndrome.
    Diamanti-Kandarakis E; Kandaraki E; Christakou C; Panidis D
    Obes Rev; 2009 Jul; 10(4):431-41. PubMed ID: 19413702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiometabolic risks in PCOS: a review of the current state of knowledge.
    Kakoly NS; Moran LJ; Teede HJ; Joham AE
    Expert Rev Endocrinol Metab; 2019 Jan; 14(1):23-33. PubMed ID: 30556433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New adolescent polycystic ovary syndrome perspectives.
    Alemzadeh R; Kansra AR
    Minerva Pediatr; 2011 Feb; 63(1):35-47. PubMed ID: 21311428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Polycystic ovary syndrome. New pathophysiological discoveries--therapeutic consequences].
    Svendsen PF; Nilas L; Nørgaard K; Madsbad S
    Ugeskr Laeger; 2005 Aug; 167(34):3147-51. PubMed ID: 16117910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PCOS: metabolic impact and long-term management.
    Carmina E
    Minerva Ginecol; 2012 Dec; 64(6):501-5. PubMed ID: 23232534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interventions for the metabolic dysfunction in polycystic ovary syndrome.
    Bozdag G; Yildiz BO
    Steroids; 2013 Aug; 78(8):777-81. PubMed ID: 23624033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular risk in women with polycystic ovary syndrome.
    Giallauria F; Orio F; Palomba S; Lombardi G; Colao A; Vigorito C
    J Cardiovasc Med (Hagerstown); 2008 Oct; 9(10):987-92. PubMed ID: 18799960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adolescence and polycystic ovary syndrome: current concepts on diagnosis and treatment.
    Spritzer PM; Motta AB
    Int J Clin Pract; 2015 Nov; 69(11):1236-46. PubMed ID: 26289303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pluripotential effects of hypolipidemic treatment for polycystic ovary syndrome (PCOS): dyslipidemia, cardiovascular risk factors and beyond.
    Economou F; Xyrafis X; Christakou C; Diamanti-Kandarakis E
    Curr Pharm Des; 2011; 17(9):908-21. PubMed ID: 21418035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polycystic ovary syndrome and cardiometabolic risk: Opportunities for cardiovascular disease prevention.
    Osibogun O; Ogunmoroti O; Michos ED
    Trends Cardiovasc Med; 2020 Oct; 30(7):399-404. PubMed ID: 31519403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment options of polycystic ovary syndrome in adolescence.
    Zapanti E; Kiapekou E; Loutradis D
    Pediatr Endocrinol Rev; 2006 Jan; 3 Suppl 1():208-13. PubMed ID: 16641862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New paradigms in PCOS: impaired glucose tolerance and cardiovascular risk. Clinical approach.
    Ravn P
    Minerva Ginecol; 2015 Apr; 67(2):217-23. PubMed ID: 25668421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin resistance and polycystic ovary syndrome.
    Galluzzo A; Amato MC; Giordano C
    Nutr Metab Cardiovasc Dis; 2008 Sep; 18(7):511-8. PubMed ID: 18657405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polycystic ovary syndrome. Long term sequelae and management.
    Legro RS
    Minerva Ginecol; 2002 Apr; 54(2):97-114. PubMed ID: 12032449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: who is really at risk?
    Daan NM; Louwers YV; Koster MP; Eijkemans MJ; de Rijke YB; Lentjes EW; Fauser BC; Laven JS
    Fertil Steril; 2014 Nov; 102(5):1444-1451.e3. PubMed ID: 25239303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.